Company intelligence / Profile preview

Skyline Biosciences

Chicago, Illinois, United Statesprnewswire.com ↗

Ownership: Private
Development stage: Phase 3

Overview

Skyline Biosciences is developing first-in-kind therapies for premalignant and malignant oral lesions, aiming to extend and improve quality of life for patients with oral oncology conditions. Its lead program, SBS-101, was in a Phase I clinical trial to evaluate safety and pharmacokinetics in patients with oral pre-malignant lesions; however, the trial was withdrawn before completion and no clinical data has been reported[1][2].

Therapeutic areas: Oncology
Modalities: Small molecules (oral adhesive film)
Industry: Biotech

Drug pipeline

2 assets

D-Fi

Phase 3

Indications: Recessive dystrophic epidermolysis bullosa, Dominant dystrophic epidermolysis bullosa

1 more asset in the full pipeline.

Request access →

Partnerships

Paragon Biosciences

Beyond the preview

Go deeper on Skyline Biosciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Skyline Biosciences.

Explore the full profile